Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK-A16037)

Banerjee, S; Tovey, H; Bowen, R; Folkerd, E; Kilburn, L; McLachlan, J; Hall, M; Tunariu, N; Attygalle, A; Lima, JPDSN; Perry, S; Chatfield, P; Hills, M; Kaye, S; Attard, G; Dowsett, M; Bliss, JM

View/Open

Published version (821.0Kb)

Publication Date

2020-12-01

ICR Author

Bliss, Judith

Folkerd, Elizabeth

Kaye, Stanley Bernard

Dowsett, Mitch

Kilburn, Lucy

Author

Banerjee, S

Tovey, H

Bowen, R

Folkerd, E

Kilburn, L

McLachlan, J

Hall, M

Tunariu, N

Attygalle, A

Lima, JPDSN

Perry, S

Chatfield, P

Hills, M

Kaye, S

Attard, G

Dowsett, M

Bliss, JM

Type

Journal Article

Subject

Science & Technology

Life Sciences & Biomedicine

Oncology

abiraterone

androgen receptor

CYP17 inhibitor

low grade serous

ovarian cancer

Research team

Clinical Trials & Statistics Unit

Medicine Drug Development Unit (Kaye)

Endocrinology

Language

English

License start date

2020-12-01

Citation

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12 pp. ? - ? (13)

Publisher

SAGE PUBLICATIONS LTD

Publications Repository

Publications Repository